Nektar Therapeutics(NKTR)
SAN FRANCISCO, CABiotechnology
Focus: Nektar Therapeutics is a San Francisco-based public biotech company developing small molecules and biologics across oncology, immunology, infectious diseases, dermatology, and metabolic disorders. The company operates as a mid-stage clinical-stage biotech with a diversified pipeline but limited approved products generating revenue.
Profile data last refreshed 25m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
10
Should You Work at Nektar Therapeutics?
AI assessmentNektar is a high-risk, high-reward clinical-stage biotech with multiple shots on goal but precarious near-term cash position; best suited for scientists and clinicians betting on pipeline success and comfortable with restructuring risk.
Why Work Here
- Broad therapeutic portfolio spanning 5+ disease areas (oncology, immunology, dermatology, metabolic diseases) offers exposure to multiple clinical programs and modalities including combination approaches with checkpoint inhibitors
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$98M
Pipeline & Clinical Trials
Placebo
PsoriasisClinical Trials (3)
NCT07711418A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Phase 3Help build intelligence for Nektar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.